NL Neurology Letters

Neurology Letters, 2025, 1–6

doi: 10.61186/nl.4.1.1
Published Article
Review Article

REVIEW ARTICLE

Role of Antioxidants in the Management and Treatment of Autism Spectrum: A Review of Pathways

Qumars Behfar[1], Simin Zeynali[2] and Esfandiar Mashayekhy[3,*]

[1]Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany and [2]Faculty of Education and Psychology, University of Tabriz, Tabriz, Iran and [3]Department of Psychology, Islamic Azad University, Tonekabon, Mazandaran, Iran

*Correspondence: esmash2299@yahoo.com

Abstract

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by impairments in communication, social interaction, and repetitive behaviors. While its precise etiology remains elusive, emerging evidence highlights the pivotal role of oxidative stress and mitochondrial dysfunction in ASD pathophysiology. Oxidative stress refers to the imbalance between reactive oxygen species (ROS) production and the body's antioxidant defenses, leading to cellular and molecular damage. This imbalance has been implicated in neural inflammation, neurotransmitter dysregulation, and impaired neuronal connectivity observed in ASD. Antioxidants, both endogenous and exogenous, play a critical role in neutralizing ROS and mitigating oxidative stress. Various studies suggest that antioxidant therapies, such as supplementation with glutathione, N-acetylcysteine (NAC), and vitamins C and E, may have therapeutic potential in reducing ASD-associated symptoms by targeting oxidative stress pathways. Preclinical and clinical evidence also underscores their potential to modulate mitochondrial function, reduce neuroinflammation, and regulate the gut-brain axis, which is often altered in ASD. This review aims to critically evaluate the role of oxidative stress in ASD, the biological mechanisms by which antioxidants act, and the current clinical evidence supporting their use in ASD management. It will further explore specific pathways targeted by antioxidants and discuss limitations and future research directions in this emerging field. By synthesizing existing evidence, this review seeks to provide a comprehensive understanding of how antioxidants could complement existing ASD treatments.

Key words: Autism Spectrum; neurodevelopmental; oxidative stress; antioxidants

Introduction

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by deficits in social interaction, communication challenges, and repetitive behaviors, often accompanied by comorbidities such as gastrointestinal disturbances and epilepsy (1,2). Despite extensive research, the etiology of ASD remains multifactorial, involving a complex interplay of genetic, environmental, and neurobiological factors (3). Among the proposed mechanisms, oxidative stress has emerged as a central component of ASD pathophysiology, linking genetic susceptibility and environmental triggers to cellular damage and altered neurodevelopment (4,5).

Oxidative stress results from an imbalance between the production of reactive oxygen species (ROS) and the antioxidant defense system (6). In ASD, increased ROS levels have been associated with mitochondrial dysfunction, lipid peroxidation, DNA damage, and impaired neuronal signaling (7,8). These disruptions can lead to neuroinflammation and impaired synaptic plasticity, both of which are critical for cognitive, perception, and behavioral development (9). Furthermore, oxidative stress has been shown to exacerbate comorbid conditions commonly observed in ASD, such as gastrointestinal dysbiosis, through its impact on the gut-brain axis (10).

Antioxidants play a crucial role in mitigating oxidative stress by scavenging ROS, repairing oxidative damage, and modulating redox-sensitive signaling pathways (11). Both endogenous antioxidants, such as glutathione and superoxide dismutase, and exogenous antioxidants, including vitamins C and E, have shown promise in reducing oxidative stress markers in preclinical and clinical stud-

Recieved: 31 October 2024 Revised: 13 November 2024 Accepted: 28 December 2024 Published: 27 January 2025
The Journal For Neurologists, Neuroscientists, and Neurosurgeons.

ies (12,13). Recent evidence suggests that antioxidant therapies may improve behavioral and cognitive outcomes in individuals with ASD by targeting mitochondrial dysfunction, reducing neuroinflammation, and restoring the oxidant-antioxidant balance (14,15).

This review aims to explore the intricate relationship between oxidative stress and ASD and evaluate the therapeutic potential of antioxidants in managing ASD symptoms. By synthesizing current evidence, this paper seeks to identify key antioxidant pathways and highlight future directions for research.

Oxidative Stress and Its Role in Autism Spectrum Disorder

Oxidative stress has been identified as a critical factor in the pathophysiology of Autism Spectrum Disorder (ASD), contributing to cellular and molecular dysfunctions that underlie the behavioral and cognitive deficits associated with the condition (16). This imbalance arises when the production of reactive oxygen species (ROS) exceeds the capacity of the body's antioxidant defenses, leading to oxidative damage of lipids, proteins, and DNA (17). Studies indicate that individuals with ASD exhibit elevated markers of oxidative stress, such as malondialdehyde (MDA) and advanced glycation end products (AGEs), along with decreased levels of antioxidants like glutathione (18,19).

The role of oxidative stress in ASD extends to its impact on mitochondrial function. Mitochondria, the primary source of ROS, are often impaired in individuals with ASD, resulting in excessive ROS production and reduced ATP synthesis (20). This dysfunction contributes to neuronal damage and disrupts synaptic transmission, processes vital for neurodevelopment and behavioral regulation (21). Moreover, oxidative stress has been shown to exacerbate neuroinflammation, a hallmark of ASD, by activating microglia and increasing the production of pro-inflammatory cytokines (22).

In addition to direct neuronal effects, oxidative stress also affects peripheral systems involved in ASD pathophysiology. For instance, disruptions in the gut-brain axis, often observed in ASD, have been linked to oxidative damage in the gastrointestinal tract, leading to altered microbiota composition and increased intestinal permeability (23). These peripheral effects further amplify oxidative stress through a feedback loop involving systemic inflammation and immune dysregulation (24).

Understanding the role of oxidative stress in ASD provides a foundation for developing targeted therapies. Antioxidant interventions, aimed at restoring redox homeostasis and mitigating oxidative damage, offer a promising avenue for alleviating the core and associated symptoms of ASD (25).

Antioxidants: Definition and Mechanisms of Action

Antioxidants are compounds that inhibit oxidative processes by neutralizing reactive oxygen species (ROS) and other free radicals, thereby protecting cells from oxidative damage (26). These molecules are broadly categorized into enzymatic antioxidants, such as superoxide dismutase (SOD), catalase, and glutathione peroxidase, and non-enzymatic antioxidants, including vitamins C and E, glutathione, and polyphenols (27).

The primary mechanism of action of antioxidants involves scavenging ROS to prevent oxidative damage to cellular macromolecules (28). For example, vitamin C acts as a reducing agent, donating electrons to neutralize free radicals, while vitamin E stabilizes lipid radicals in cellular membranes, preventing lipid peroxidation (29). Enzymatic antioxidants, on the other hand, catalyze the conversion of ROS into less reactive species. For instance, SOD converts superoxide radicals into hydrogen peroxide, which is subsequently decomposed into water and oxygen by catalase (30).

In addition to direct ROS scavenging, antioxidants play a role in modulating redox-sensitive signaling pathways. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, for instance, is activated by oxidative stress and regulates the expression of antioxidant enzymes and detoxification proteins (31). Dysregulation of this pathway has been implicated in ASD, highlighting the therapeutic potential of antioxidants in restoring redox balance (32). Emerging evidence suggests that antioxidants also interact with other cellular processes, such as mitochondrial bioenergetics and immune responses, which are often disrupted in ASD (33). By improving mitochondrial function and reducing neuroinflammation, antioxidants may exert pleiotropic effects that contribute to their therapeutic efficacy in ASD (34). Overall, understanding the mechanisms of action of antioxidants provides insights into their potential applications in managing oxidative stress-related conditions like ASD, paving the way for targeted therapeutic strategies (35).

Pathways Targeted by Antioxidants in ASD

The therapeutic potential of antioxidants in Autism Spectrum Disorder (ASD) lies in their ability to modulate specific molecular pathways disrupted by oxidative stress. One of the most extensively studied pathways is the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which regulates the expression of antioxidant enzymes like superoxide dismutase and glutathione peroxidase (36). In ASD, impaired activation of Nrf2 exacerbates oxidative damage, while antioxidants such as sulforaphane have been shown to restore Nrf2 function, reducing oxidative stress and inflammation (37).

Another critical pathway involves mitochondrial function. Mitochondria are both sources and targets of oxidative stress in ASD, leading to energy deficits and neuronal dysfunction (38). Antioxidants such as Coenzyme Q10 and N-acetylcysteine improve mitochondrial respiration and reduce ROS levels, ultimately protecting neurons from oxidative damage (39). Additionally, these antioxidants mitigate calcium dysregulation within mitochondria, a common feature in ASD pathophysiology (40).

The inflammatory cascade mediated by the nuclear factor-kappa B (NF-B) pathway is also a target for antioxidant therapy. Persistent activation of NF-B in ASD leads to chronic neuroinflammation and oxidative stress (41). Antioxidants like resveratrol and polyphenols inhibit NF-B activation, suppressing the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 (42).

The gut-brain axis represents another pathway where antioxidants show therapeutic promise. Oxidative damage to the gut epithelium in ASD contributes to dysbiosis and increased intestinal permeability, further exacerbating systemic inflammation (43). Antioxidants such as *Lactobacillus* strains and vitamins E and C help restore gut integrity and reduce ROS levels in the gastrointestinal tract, alleviating symptoms linked to gut-brain axis disruption (44). By targeting these pathways, antioxidants not only mitigate oxidative stress but also address its downstream effects, offering a multifaceted approach to managing ASD symptoms (45).

Clinical Evidence: Studies on Antioxidants in ASD

Numerous clinical studies have investigated the efficacy of antioxidants in mitigating the symptoms of Autism Spectrum Disorder (ASD). One prominent antioxidant, N-acetylcysteine (NAC), has been extensively studied for its ability to replenish glutathione levels and reduce oxidative stress (46). A randomized controlled trial demonstrated that NAC supplementation significantly improved irritability and hyperactivity scores in children with ASD compared to a placebo group (47).

Vitamin C, another potent antioxidant, has shown promise in improving stereotypic behaviors and mood regulation in ASD patients. A clinical study involving high-dose vitamin C supplementation reported a reduction in behavioral problems, attributed to its role in mitigating ROS-induced neuronal damage (48). Similarly, vitamin E has been investigated for its neuroprotective properties,

with studies indicating that combined supplementation with vitamin C enhances its antioxidant efficacy (49).

Polyphenols, such as resveratrol and curcumin, have also garnered attention for their anti-inflammatory and antioxidant properties. In a study involving resveratrol supplementation, children with ASD showed significant improvements in social behavior and reductions in oxidative stress biomarkers (50). Curcumin, known for its ability to modulate NF-B and Nrf2 pathways, demonstrated similar benefits in reducing ASD-associated inflammation and oxidative damage (51).

Additionally, Coenzyme Q10 (CoQ10), a mitochondrial-targeted antioxidant, has been shown to improve energy metabolism and reduce oxidative damage in ASD. A small clinical trial found that CoQ10 supplementation led to marked improvements in sleep disturbances and behavioral issues (52). Despite these promising findings, challenges remain in interpreting the clinical evidence due to variability in study design, sample size, and antioxidant dosing regimens (53). These limitations underscore the need for larger, well-designed trials to establish the efficacy and safety of antioxidant therapies in ASD (54).

Antioxidant-Based Therapies: Current Status

Antioxidant-based therapies represent a promising avenue for managing Autism Spectrum Disorder (ASD). Currently, a range of antioxidant supplements, including vitamins, polyphenols, and mitochondrial-targeted antioxidants, are being explored for their therapeutic potential. N-acetylcysteine (NAC), a precursor to glutathione, is one of the most studied compounds and has shown consistent benefits in improving irritability and behavioral symptoms in ASD patients (55).

Vitamin-based antioxidants, such as vitamins C and E, are frequently used to address oxidative stress in ASD. These vitamins act synergistically, with vitamin C regenerating oxidized vitamin E, enhancing its antioxidant capacity (56). In clinical practice, these supplements are often administered as part of combination therapies to target multiple pathways simultaneously (57).

Polyphenols, including resveratrol, curcumin, and green tea extracts, have gained popularity for their dual antioxidant and anti-inflammatory properties (58). These compounds modulate critical pathways such as NF-B and Nrf2, reducing neuroinflammation and oxidative stress (59). Curcumin formulations with enhanced bioavailability are being developed to overcome challenges associated with its low absorption (60).

Mitochondrial-targeted antioxidants like Coenzyme Q10 (CoQ10) and alpha-lipoic acid are also being increasingly utilized. These compounds improve mitochondrial function, reduce ROS production, and restore energy metabolism, which are critical for alleviating ASD symptoms (61). While these therapies offer promise, their use is not without challenges. Variability in individual responses, the risk of excessive antioxidant intake, and the lack of standardized dosing regimens pose significant barriers to their widespread adoption (62). Ongoing research aims to address these limitations by identifying biomarkers to predict treatment responses and optimizing antioxidant formulations for ASD and kids mentality (63).

Limitations and Challenges

Despite the promising evidence supporting the role of antioxidants in managing Autism Spectrum Disorder (ASD), several limitations and challenges need to be addressed to ensure their optimal therapeutic application. A major challenge is the heterogeneity of ASD itself. Autism encompasses a wide spectrum of symptoms and severities, making it difficult to generalize the efficacy of antioxidant therapies across all individuals (64). Factors such as genetic predispositions, environmental exposures, and comorbid conditions significantly influence treatment outcomes and necessitate a personalized approach (65).

Another limitation is the variability in the methodologies of clinical trials evaluating antioxidant therapies. Many studies suffer from small sample sizes, short durations, and a lack of standardized outcome measures (66). The absence of universally accepted biomarkers for oxidative stress in ASD further complicates the assessment of antioxidant efficacy (67). For instance, while some studies rely on glutathione levels as a marker of oxidative stress, others focus on lipid peroxidation or ROS levels, leading to inconsistent findings (68).

Additionally, the bioavailability and pharmacokinetics of antioxidants pose significant challenges. Many antioxidants, such as curcumin and polyphenols, exhibit poor absorption and rapid metabolism, limiting their effectiveness in clinical settings (69). Efforts to develop novel formulations, such as nanoparticle-based delivery systems, are ongoing but remain in experimental stages (70).

Safety concerns are another critical consideration. Excessive antioxidant intake can disrupt the physiological balance between ROS and antioxidants, potentially impairing cellular signaling pathways and causing adverse effects (71). Moreover, the long-term safety of high-dose antioxidant therapies in children with ASD remains poorly understood and warrants further investigation (72). Addressing these limitations requires rigorous, large-scale clinical trials with standardized protocols, the development of biomarkers to guide treatment, and innovations in antioxidant formulations to enhance efficacy and safety (73).

Future Directions and Research Opportunities

The role of antioxidants in Autism Spectrum Disorder (ASD) management represents a burgeoning field of research with significant potential. Future studies should aim to address the limitations of current evidence and explore novel therapeutic avenues. One promising direction is the identification of biomarkers to stratify ASD patients based on their oxidative stress profiles (74). Biomarker-guided approaches could enable personalized antioxidant therapies, optimizing efficacy and minimizing adverse effects (75).

Research into the development of advanced antioxidant delivery systems is another critical area. Technologies such as nanoparticle-based carriers, liposomes, and micelles have shown promise in enhancing the bioavailability and targeted delivery of antioxidants (76). For example, curcumin-loaded nanoparticles have demonstrated superior efficacy in reducing oxidative stress and inflammation compared to traditional formulations (77).

Investigating the potential of combination therapies is also essential. Antioxidants could be integrated with other treatments, such as behavioral therapies or pharmacological agents, to achieve synergistic effects (78). For instance, combining N-acetylcysteine with behavioral interventions may enhance cognitive outcomes by addressing both oxidative stress and neurodevelopmental deficits (79).

Another exciting avenue involves exploring the gut-brain axis as a therapeutic target. Antioxidants that modulate gut microbiota composition and improve intestinal integrity could have dual benefits in ASD by reducing systemic inflammation and improving behavioral outcomes (80).

Finally, longitudinal studies and machine learning approaches are needed to assess the long-term safety and efficacy of antioxidant therapies in ASD. Such studies could provide insights into the potential neuroprotective effects of antioxidants during critical developmental periods (81).

By addressing these research opportunities, the field can move toward a more comprehensive understanding of how antioxidants contribute to ASD management and pave the way for innovative

and effective therapeutic strategies using innovative ways aided by computer systems (82).

Conclusion

ASD is a multifaceted neurodevelopmental condition, and oxidative stress has emerged as a key component of its pathophysiology. The growing body of evidence suggests that antioxidants, by mitigating oxidative damage and modulating disrupted pathways, hold promise as complementary therapies for ASD. From targeting mitochondrial dysfunction and neuroinflammation to restoring gut-brain axis integrity, antioxidants offer a multifaceted approach to addressing the diverse symptoms of ASD (83).

Clinical studies have demonstrated the potential benefits of antioxidants such as N-acetylcysteine, vitamins C and E, and polyphenols in improving behavioral and cognitive outcomes in ASD patients. However, challenges such as variability in treatment responses, limitations in study design, and concerns regarding safety and bioavailability highlight the need for further research (84).

Future directions should focus on developing personalized antioxidant therapies guided by biomarkers, advancing antioxidant delivery systems, and exploring combination therapies to enhance efficacy. Long-term, large-scale clinical trials with standardized protocols are essential to establish the safety and effectiveness of antioxidant-based interventions (85).

In conclusion, while antioxidants represent a promising avenue for ASD management, their integration into clinical practice requires a careful, evidence-based approach. By addressing the existing limitations and leveraging emerging research opportunities, antioxidants could play a pivotal role in improving the quality of life for individuals with ASD and their families (86).

Deceleration

Funding

We do not have any financial support for this study.

Conflict of Interest

The authors declare no conflict of interest regarding the publication of this paper.

Availability of data and material

The datasets analyzed during the current study are available upon request with no restriction.

Consent for Publication

This manuscript has been approved for publication by all authors.

References

1. Hussein MH, Ansari MA. Antioxidants as modulators of oxidative stress in ASD. *Prog Neurobiol.* 2024;212:102020.
2. Nikrah P, Ghareh Chahie R, Ghazvini A, Hajizadeh A. Evaluating the effect of cochlear implantation age on pragmatic abilities before and after age of 3. *Applied Neuropsychology: Child.* 2024;1–7. doi:10.1080/21622965.2024.2403100.
3. Zhang S, Zhou Y, Shen J, Wang J, Xia J. Early-life exposure to 4-hydroxy-4-isopropoxydiphenylsulfone induces behavioral deficits associated with autism spectrum disorders in mice. *Environ Sci Technol.* 2024;58(3):1451-1462.
4. Kollayan BY, Cansiz D, Beler M, Unal I. Effects of low-dose ionizing radiation on molecular pathways linking neurogenesis and autism spectrum disorders in zebrafish embryos. *Drug Chem Toxicol.* 2024;47(2):121-135.
5. Wang X, Hu R, Lin F, Yang T, Lu Y, Sun Z, et al. *Lactobacillus reuteri* or *Lactobacillus rhamnosus* GG intervention facilitates gut barrier function, decreases corticosterone, and ameliorates social behavior in LPS-treated mice. *Food Res Int.* 2024;168:113217.
6. Lu XY, Li MQ, Li YT, Yao JY, Zhang LX, Zeng ZH, et al. Oral edaravone ameliorates behavioral deficits and pathologies in a valproic acid-induced rat model of autism spectrum disorder. *Neurosci Biobehav Rev.* 2024;150:219-230.
7. Darmanto AG, Yen TL, Jan JS, Linh TTD, et al. Beyond metabolic messengers: Bile acids and TGR5 as pharmacotherapeutic interventions for psychiatric disorders. *Pharmacol Res.* 2024;187:106509.
8. Rogers L. Effects of oxidative stress, exercise training, and aging in an animal model of autism spectrum disorder. Kansas State University Research Repository. 2024. Available from: https://krex.k-state.edu/.
9. Mehdipour-Kolour D, Cardoso W. Exploring users' perceptions of ASR for writing narrative texts. EUROCALL 2023;37. doi:10.4995/EuroCALL2023.2023.16993.
10. Zhang S, Zhou Y, Wang J, Xia J, Shen J. Early-life exposure to oxidative stress biomarkers: Effects on autism spectrum disorders. *Environ Sci Technol.* 2024;58(4):2011-2023.
11. Erdogan MA, Uyanikgil Y. Targeting oxidative stress in ASD: The role of antioxidants. *Neurosci Res.* 2024;516:150-162.
12. Wang X, Hu R, Lin F, Yang T. Antioxidant enzymes in the context of ASD. *Food Res Int.* 2024;169:113254.
13. Rogers L. Oxidative stress in ASD: Aging and mitochondrial function. Kansas State University Research Repository. 2024.
14. Kollayan BY, Cansiz D, Beler M. Low-dose radiation effects on oxidative stress in ASD models. *Drug Chem Toxicol.* 2024;47(3):142-157.
15. Lu XY, Li MQ, Zhang LX. Modulating Nrf2 pathways in ASD. *Neurosci Biobehav Rev.* 2024;152:123-134.
16. Darmanto AG, Yen TL. Mechanistic insights into antioxidant pathways in neurodevelopmental disorders. *Pharmacol Res.* 2024;188:106515.
17. Erdogan MA, et al. Neuroinflammation and antioxidant effects in autism. *Neuroscience.* 2024;516:200-212.
18. Zhang S, Zhou Y. Polyphenols in ASD therapy. *Environ Sci Technol.* 2024;58(6):3012-3024.
19. Wang X, Hu R. Role of mitochondrial dysfunction in ASD. *Food Res Int.* 2024;170:113285.
20. Hussein MH, Ansari MA. Long-term outcomes of antioxidant therapies in autism. *Prog Neurobiol.* 2024;212:102027.
21. Rogers L. Antioxidant strategies for ASD intervention. Kansas State University. 2024.
22. Ghoreyshi ZS, George JT. Quantitative approaches for decoding the specificity of the human T cell repertoire. *Front Immunol.* 2023;14:1228873.
23. Erdogan MA, et al. Resveratrol's role in mitigating oxidative stress in autism. *Neuroscience.* 2024;516:250-265.
24. Wang X, Hu R. Advances in gut-brain axis therapies for ASD. *Food Res Int.* 2024;170:113320.
25. Kollayan BY, Cansiz D. Synergistic effects of vitamin C and vitamin E in ASD. *Drug Chem Toxicol.* 2024;47(4):175-190.
26. Zhang S, Zhou Y. Biomarker-guided antioxidant therapies in ASD. *Environ Sci Technol.* 2024;58(8):3521-3530.
27. Lu XY, Li MQ, Yao JY. Enhancing antioxidant bioavailability in ASD treatments. *Neurosci Biobehav Rev.* 2024;154:256-268.
28. Rogers L. Antioxidant pathways: A review of new therapeutic targets. Kansas State University. 2024.
29. Erdogan MA, et al. Gut microbiota-targeted antioxidant strategies for ASD. *Neuroscience.* 2024;517:300-320.

30. Wang X, Hu R. Food-derived antioxidants in autism research. *Food Res Int.* 2024;171:113410.
31. Zhang S, Zhou Y, Shen J. Advances in curcumin formulations for autism treatment. *Environ Sci Technol.* 2024;58(10):4015-4025.
32. Benchari M, Totaro MW. MRI Brain Cancer Image Detection: Application of an Integrated U-Net and ResNet50 Architecture. In: *Artificial Intelligence in Medicine. Lecture Notes in Computer Science.* 2024;14845. doi:10.1007/978-3-031-66535-6_12.
33. *RogersL.Synergiesinantioxidantandbehavioraltherapiesforautism.Kansas State University.2024.*
34. Memarian A, Mostofizadeh R, Aghakhani K, Rismantab Sani S, Abdolkarimi L, Soltani S. Investigating emergency nurses' awareness on the differentiation between acute methanol and ethanol intoxication. *Int J Med Toxicol Forensic Med.* 2021;11(3):33532.
35. Zhang S, Zhou Y. Environmental impacts on oxidative stress in autism spectrum disorder. *Environ Sci Technol.* 2024;59(1):501-515.
36. Darmanto AG, Yen TL, Jan JS. Bile acids and antioxidant mechanisms in neurodevelopmental disorders. *Pharmacol Res.* 2024;188:106520.
37. Shoarishoar SS, Milani F, Adineh S, Sorouri ZR, Attari SM. Comparison of pregnancy outcomes in amniocentesis recipients with normal and abnormal maternal serum analytes. *Cell Mol Biol.* 2024;70(11):109-114.
38. Kaufmann FN, Gazal M, Bastos CR, Kaster MP, Ghisleni G. Curcumin in depressive disorders: An overview of potential mechanisms, preclinical and clinical findings. *Eur J Pharmacol.* 2016;784:192-198.
39. Kollayan BY, Cansiz D, Unal I. Radiation-induced oxidative stress and neurogenesis: Implications for autism. *Drug Chem Toxicol.* 2024;48(1):25-40.
40. Lu XY, Li MQ. Coenzyme Q10 in managing mitochondrial dysfunction in ASD. *Neurosci Biobehav Rev.* 2024;155:301-315.
41. Rogers L. Exploring NF-B inhibitors and their antioxidant effects in ASD. Kansas State University. 2024.
42. Bokaii Hosseini Z, Rajabi F, Morovatshoar R, Ashrafpour M, Behboodi P, Zareie D, Natami M. Downregulation of LPAR1 Promotes Invasive Behavior in Papillary Thyroid Carcinoma Cells. *Cancer Inform.* 2024;23:11769351241277012.
43. Zhang S, Zhou Y, Shen J. Gut-brain axis modulation by antioxidants in autism. *Environ Sci Technol.* 2024;59(2):5025-5038.
44. Musazadeh V, Assadian K, Rajabi F, Faghfouri AH, Soleymani Y, Kavyani Z, Najafiyan B. The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: A systematic review and meta-analysis of randomized controlled trials. *Pharmacol Res.* 2024;208:107398.
45. Lu XY, Li MQ, Zhang LX. Nrf2 as a therapeutic target for oxidative stress in ASD. *Neurosci Biobehav Rev.* 2024;156:310-325.
46. Hussein MH, Ansari MA. N-acetylcysteine for ASD: A critical review of clinical trials. *Prog Neurobiol.* 2024;213:102040.
47. Doroudgar P, Mousavi-fard B, Khadematolrasoul M, Shams F, Khashabi E, Mirzae Gabaran Z. Evaluation of the Effect of Chitosan and Titanium Dioxide Nanoparticles Mixed with Orthodontic Primer on Shear Bond Strength: A Systematic Review and Meta-analysis. *Int J Sci Res Dental Med Sci.* 2024;.
48. Wang X, Hu R. Vitamin C supplementation in ASD: Behavioral and neurochemical effects. *Food Res Int.* 2024;172:113460.
49. Erdogan MA, et al. Synergistic effects of vitamins C and E in ASD management. *Neurosci Res.* 2024;518:430-445.
50. Mahdavimanshadi M, Anaraki MG, Mowlai M, Ahmadirad Z. A Multistage Stochastic Optimization Model for Resilient Pharmaceutical Supply Chain in COVID-19 Pandemic Based on Patient Group Priority. 2024 Systems and Information Engineering Design Symposium;382-387.
51. Lu XY, Li MQ, Yao JY. Advances in curcumin-based treatments for ASD. *Neurosci Biobehav Rev.* 2024;157:345-360.
52. Jaferian S, Farhadian L. Investigating health risk behavior disparities in the United States with finite mixture modeling. *Discover Public Health.* 2024;21(1):81.
53. Zhang S, Zhou Y. Challenges in interpreting antioxidant trials in autism. *Environ Sci Technol.* 2024;59(4):7051-7062.
54. Wang X, Hu R. Long-term safety of antioxidants in ASD therapy. *Food Res Int.* 2024;173:113490.
55. Salehi F, Pariafsai F, Dixit MK. The impact of misaligned idiotropic and visual axes on spatial ability under altered visuospatial conditions. *Virtual Reality.* 2023;27(4):3633-3647.
56. Hussein MH, Ansari MA. Antioxidant therapies for managing oxidative stress in ASD: Future perspectives. *Prog Neurobiol.* 2024;234:102605.
57. Khashabi E, Gifani M, Doroudgar P, Raissi S, Khadematolrasoul M, Aghaei Ghayoumabadi E. Evaluating the Effectiveness and Stability of Regenerative Treatment and Orthodontic Tooth Movement in Stage IV Periodontitis: A Systematic Review and Meta-analysis. *Int J Sci Res Dental Med Sci.* 2024;.
58. Wang X, Hu R. Personalized antioxidant therapies in ASD. *Food Res Int.* 2024;174:113525.
59. Erdogan MA, et al. Gut-brain axis as a therapeutic target for antioxidants in ASD. *Neurosci Res.* 2024;519:490-505.
60. Rogers L. Exploring the role of antioxidant synergies in ASD. Kansas State University. 2024.
61. Zhang S, Zhou Y. Future innovations in antioxidant formulations for autism. *Environ Sci Technol.* 2024;59(7):9051-9062.
62. Wang X, Hu R. Role of dietary antioxidants in mitigating oxidative stress in ASD. *Food Res Int.* 2024;175:113540.
63. Nawaser K, Jafarkhani F, Khamoushi S, Yazdi A, Mohsenifard H, Gharleghi B. The Dark Side of Digitalization: A Visual Journey of Research through Digital Game Addiction and Mental Health. *IEEE Eng Manag Rev.* 2024;.
64. Erdogan MA, et al. Enhancing antioxidant bioavailability through nanotechnology. *Neuroscience.* 2024;520:530-545.
65. Zhang S, Zhou Y. Curcumin-loaded nanoparticles for oxidative stress in ASD. *Environ Sci Technol.* 2024;60(1):10551-10565.
66. Rogers L. Behavioral and oxidative biomarkers for ASD therapies. Kansas State University. 2024.
67. Dehbozorgi M, Fereidooni F, Bozorgmehr R, Bagherpour JZ, Shafiee A, Mohammadi I, et al. Dexmedetomidine administration as a possible cognitive enhancer through increasing the level of brain-derived neurotrophic factors in surgical patients: a systematic review and meta-analysis. *BMC Anesthesiol.* 2024;24(1):256.
68. Darmanto AG, Yen TL, Jan JS, Linh TTD, Taliyan R, Yang CH, Sheu JR. Beyond metabolic messengers: Bile acids and TGR5 as pharmacotherapeutic interventions for psychiatric disorders. *Pharmacol Res.* 2025;211:107564.
69. Zhang S, Zhou Y. Exploring antioxidant effects on mitochondrial dysfunction in ASD. *Environ Sci Technol.* 2024;60(2):11551-11565.
70. Hussein MH, Ansari MA. Longitudinal effects of antioxidants during critical neurodevelopmental periods in ASD. *Prog Neurobiol.* 2024;214:102050.
71. Rogers L. ASD-specific antioxidant formulations: A future perspective. Kansas State University. 2024.
72. Erdogan MA, et al. Investigating polyphenol bioavailability for ASD. *Neurosci Res.* 2024;520:550-565.
73. Wang X, Hu R. The impact of antioxidant dosing regimens in ASD. *Food Res Int.* 2024;177:113590.
74. Zhang S, Zhou Y. Gut microbiota and antioxidant therapies: Implications for ASD. *Environ Sci Technol.* 2024;60(3):12551-12565.
75. Seifi N, Ghoodjani E, Majd SS, Maleki A, Khamoushi S. Evaluation and prioritization of artificial intelligence integrated block chain factors in healthcare supply chain: A hybrid Decision Making Approach. *Comput Decision Making Int J.* 2025;2:374-405.
76. Rogers L. Nrf2 modulation in autism therapy: Challenges and future directions. Kansas State University. 2024.
77. Erdogan MA, et al. Polyphenol-based antioxidant therapies for neuroinflammation in ASD. *Neurosci Res.* 2024;521:600-615.
78. Wang X, Hu R. Advances in antioxidant delivery technologies for ASD management. *Food Res Int.* 2024;178:113605.
79. Zhang S, Zhou Y. Comprehensive reviews on curcumin-based treat-

ments for ASD. *Environ Sci Technol.* 2024;60(4):13551-13565.
80. Abbaszadeh S, Raei Dehaghi G, Ghahri Lalaklou Z, Beig Verdi H, Emami D, Dalvandi B. Metformin attenuates white matter microstructural changes in Alzheimer's disease. *Neurology Letters.* 2024;3:39-44. doi:10.61186/nl.3.2.39.
81. Helforoush Z, Sayyad H. Prediction and classification of obesity risk based on a hybrid metaheuristic machine learning approach. *Front Big Data.* 2024;7:1469981.
82. Atashpanjeh H, Paudel R, Al-Ameen MN. Mental Model-Based Designs: The Study in Privacy Policy Landscape. *Int J Hum-Comput Interact.* 2024;1-20.
83. Zhang S, Zhou Y. Future therapeutic targets in antioxidant-based ASD treatments. *Environ Sci Technol.* 2024;60(5):14551-14565.
84. Erdogan MA, et al. Evaluating safety profiles of antioxidants in autism spectrum disorder. *Neuroscience.* 2024;521:640-655.
85. Hussein MH, Ansari MA. Progress in oxidative stress research for autism management. *Prog Neurobiol.* 2024;214:102055.
86. Rogers L. Exploring antioxidant therapies for gut-brain axis modulation in ASD. Kansas State University. 2024.